B. infantis EVC001 is well-tolerated and improves human milk oligosaccharide utilization in preterm infants in the neonatal intensive care unit

A prospective, open-label study was used to evaluate the tolerability and HMO-utilization capacity of B. infantis EVC001 and its effects on the fecal microbiota in thirty preterm infants <1,500 g and/or <33 weeks gestation at birth. B. infantis EVC001 was shown to be safe, well-tolerated, and efficient in colonizing the preterm infant gut and able to increase the abundance of bifidobacteria capable of metabolizing HMOs, resulting in significantly improved utilization of human milk.